SURVYR

NAMS

NewAmsterdam Pharma Company N.V.
$21.07
+$0.57 (2.78%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-46%-30%-14%+1%+17%Oct 2025Oct 2026Apr 202652w high $42.2052w low $19.58
NAMSSPY
Wall St. Highest PT $59.52 (+182.5%) Wall St. Avg PT $49.92 (+136.9%)
$20$35$51$66$81POC $34Hi $60Avg $50
Underwater Drawdown %Max DD -52.9%Current -49.2%
0.0%-52.9%
Relative Strength vs SPY-55.5% vs SPYUnderperforming
+68%0%-68%
1W
−$0.42 (1.95%)
1M
−$2.51 (10.64%)
3M
−$6.84 (24.51%)
6M
−$7.36 (25.89%)
YTD
−$14.01 (39.94%)
1Y
−$15.07 (41.70%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
15 analysts · mean score 1.31
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$21.07
Average target$49.92
+$28.85 (+136.9%) upsideaverage target vs current price
CurrentAverageMedian
Low$38.17
Median$49.92
High$59.52
12-month Wall Street target range

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$2.5B
P/E (next 12 months, estimated)-14.1
52-week range$19.58 – $42.20
Revenue growth (latest quarter vs a year ago)-80.7%
Dividend yieldNo dividend
Analyst consensusStrong Buy (15)
Average analyst price target$49.92 (+137%)

What they do

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for NAMS yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

NAMS earningsNext report in 6 days
Next report · quarter Sep 2026
Wed Nov 4, 2026Before the open
EPS consensus-$0.44
Revenue consensus–
Last 4 quarters · EPS vs estimate
Aug 5, 2026-$0.45est -$0.43−5.7%Below estimates
May 7, 2026-$0.34est -$0.41+16.5%Above estimates
Feb 18, 2026-$0.53est -$0.37−45.3%Below estimates
Nov 5, 2025-$0.53est -$0.34−54.0%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-27 17:53:23 ET
24-1125-0225-0525-0825-1126-0226-0526-08-0.900.00
EstimateActual (beat)Actual (miss)

News & catalysts

More news
Early Toxicity Testing - Market Size, Share, Industry Trends, and Growth Forecasts (2026-2031) | NAMs, AI, and Organ-on-Chip Adoption Propel Market to $2.29 Billion
GlobeNewswire · Oct 27
Does NewAmsterdam Pharma’s (NAMS) Genotype-Targeted SPINOZA Trial Reframe Obicetrapib’s Long-Term Alzheimer’s Strategy?
Simply Wall St. · Oct 13
NewAmsterdam PREVAIL Interim Faces 'Considerable' Risk, RBC Says
MT Newswires · Oct 05
RBC Cuts Price Target on NewAmsterdam Pharma to $42 From $50, Keeps Outperform, Speculative Risk
MT Newswires · Oct 05
Group 1 Automotive and 4 More Stocks See Action From Activist Investors
Barrons.com · Oct 02
Insider trades
Kastelein Johannes Jacob Pieter
Director, Chief Scientific Officer · 2026-09-30
Sell
$1.3M
Davidson Michael H.
Director, Chief Executive Officer · 2026-09-14
Buy
$226.5K
Smither John W
Director · 2026-09-04
Sell
$40.5K
Kastelein Johannes Jacob Pieter
Director, Chief Scientific Officer · 2026-08-24
Sell
$3.4M
Kooij Louise Frederika
Chief Accounting Officer · 2026-07-20
Sell
$92.4K
Kooij Louise Frederika
Chief Accounting Officer · 2026-07-20
Sell
$990.0K
Kooij Louise Frederika
Chief Accounting Officer · 2026-07-20
Sell
$2.1M
None
None · None
Sell
–

Stats refreshed 2026-10-27 17:53:23 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026